Format

Send to

Choose Destination
See comment in PubMed Commons below
Rheumatology (Oxford). 2010 Feb;49(2):259-63. doi: 10.1093/rheumatology/kep371. Epub 2009 Dec 9.

Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts.

Author information

1
Centre for Rheumatology, University College London (Royal Free Campus), London, UK.

Abstract

OBJECTIVE:

The transcription factor peroxisome proliferator-activated receptor (PPAR)-gamma plays an important role in controlling cell differentiation. The aim of the present study was to examine whether PPAR-gamma expression was reduced in skin scleroderma fibroblasts and whether PPAR-gamma agonists could suppress the persistent fibrotic phenotype of skin scleroderma fibroblasts.

METHODS:

Dermal fibroblasts were isolated from site-, age- and sex-matched healthy individuals and lesional areas of individuals with dcSSc. Western blot and collagen gel contraction analyses were used to detect protein expression in the presence or absence of the PPAR-gamma agonist rosiglitazone.

RESULTS:

PPAR-gamma expression was reduced in dcSSc fibroblasts. The PPAR-gamma agonist rosiglitazone alleviated the persistent fibrotic phenotype of dcSSc fibroblasts.

CONCLUSION:

Rosiglitazone may alleviate the extent of fibrosis in dcSSc.

PMID:
20007285
DOI:
10.1093/rheumatology/kep371
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center